Dr. Aaron Vinik addresses the question of why so much current diabetes therapy is focused on lowering blood glucose levels despite evidence that for some cardiovascular issues, this doesn’t have as much of an impact as other drugs which may have less BG-lowering capacities….

Dr. Aaron Vinik continues his discussion of why the “glucophiles” and those promoting lower lipids may be missing a larger picture which involves dopamine levels in the brain. In this in-depth analysis, he talks about what we may have been missing all along and some of the past research studies …

In answering a question on the status of cycloset as a glucose lowering drug, Dr. Aaron Vinik delves into the deeper question of how glycemic control relates to effective cardiovascular therapy. He talks about the ACCORD trial and what we learned from that, and his answers may surprise you….

Dr. Vinik discusses how the “best” A1c is different for different populations and cultures, his own preference for A1c, and lets us know what the best sport to reduce A1c is.  

Dr. Vinik explains exactly how GLP-1’s work and also discusses his studies on the cardiovascular benefits of bromocriptine.   

Dr. Vinik talks about the use of metformin and the problems of B12 deficiency, but also explains how metformin may be able to slow down the proliferation of cancer cells.  

Aaron I. Vinik, MD, PhD, FCP, MACP, talks about when the circumstances are best for initiating intensive therapy and when they are not, giving the specific risk factors that should be taken into account according to the most recent studies….  

Dr. Vinik breaks down the hard lessons of the ACCORD study, including the identification of those particularly at cardiovascular risk, and discusses the importance of treating to avoid macrovascular complications rather than achieving a specific A1c.  

Aaron I. Vinik, MD, PhD, FCP, MACP Eastern Virginia Medical School, Strelitz Diabetes and Neuroendocrine Center Department of Medicine, Division of Endocrinology and Metabolism Norfolk, Virginia USA Topiramate is a structurally novel anti-epileptic drug effective in management of various types of epilepsy and prevention of migraine headaches. A sulfamate substituted …

One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik, Director of Research and Neuroendocrine Unit, EVMS Strelitz Diabetes Research Center, shares his views on early insulin initiation. The natural history of type 2 Diabetes (T2DM) is a progressive worsening of glycemic control as a consequence of …